NicOx Announces Pfizer Initiates Phase 2 Clinical Development For PF-03187207 In Japan

NicOx S.A. (Euronext Paris: COX) announced that Pfizer Inc (NYSE: PFE) has initiated a dose-ranging phase 2 clinical study for PF-03187207 in Japan. PF-03187207 is a new experimental medicine for the treatment of glaucoma, which is currently in an ongoing phase 2 proof-of-concept study in the United States (see press releases of March 28 and 29, 2007).

More: continued here

Filed under: Clinical Trials on January 4th, 2008